XLO Xilio Therapeutics, Inc. - Common Stock
$9,65
Precio · Ago 18, 2026
Fundamentales a fecha de Ago 12, 2026
Rango 52S
$1–$10
97% of range
Calificación del Analista
STRONG BUY
5 analysts
Precio Objetivo
$20
+107% upside
P/E (TTM)
-2.3
ROE
-165.5%
Margen de Beneficio Neto
-80.0%
XLO Instantánea de la Acción Precio, capitalización bursátil, P/E, BPA, ROE, deuda/capital, rango de 52 semanas
Precio
$9.65
Capitalización Bursátil
$44M
P/E (TTM)
-2.3
BPA (TTM)
$-4.19
Ingresos (TTM)
$44M
Rendimiento div.
—
ROE
-165.5%
Deuda/Capital
—
Rango 52S
$1 – $10
XLO Gráfico del Precio de la Acción OHLCV diario con indicadores técnicos — desplace, amplíe y personalice su vista
Configure
Rendimiento a 10 años Tendencias de ingresos, beneficio neto, márgenes y BPA
Ingresos y Beneficio Neto
$44M
2024-12-31
→
2025-12-31
BPA
$-4.19
2020-12-31
→
2025-12-31
Flujo de caja libre
$-6M
2021-12-31
→
2025-12-31
Márgenes
-80.0%
Valoración Ratios P/E, P/S, P/B, EV/EBITDA: ¿está la acción cara o barata?
Métrica
Tendencia a 5 años
XLO
Mediana de Pares
P/E (TTM)
-2.3
—
P/S (TTM) (P/V (TTM))
1.0
100.5
P/B (P/C)
1.2
1.6
Price / FCF (Precio / FCF)
-7.9
—
Rentabilidad Márgenes brutos, operativos y netos; ROE, ROA, ROIC
Métrica
Tendencia a 5 años
XLO
Mediana de Pares
Operating Margin (Margen Operativo)
-95.9%
—
Net Profit Margin (Margen de Beneficio Neto)
-80.0%
-1526.8%
ROA
-31.0%
-55.4%
ROE
-165.5%
-105.3%
ROIC
-119.0%
—
Salud financiera Deuda, liquidez, solvencia — solidez del balance general
Métrica
Tendencia a 5 años
XLO
Mediana de Pares
Current Ratio (Ratio corriente)
2.6
4.4
Quick Ratio (Ratio Rápido)
2.4
—
Crecimiento Crecimiento de ingresos, BPA y beneficio neto: interanual, CAGR a 3 años, CAGR a 5 años
Métrica
Tendencia a 5 años
XLO
Mediana de Pares
Revenue YoY (Ingresos interanuales)
589.9%
—
Eficiencia de capital Rotación de activos, rotación de inventario, rotación de cuentas por cobrar
Métrica
Tendencia a 5 años
XLO
Mediana de Pares
XLO Consenso de analistas Opiniones de analistas alcistas y bajistas, precio objetivo a 12 meses, potencial alcista
COMPRA
5 analistas
- Compra fuerte 2 40,0%
- Compra 2 40,0%
- Mantener 1 20,0%
- Venta 0 0,0%
- Venta fuerte 0 0,0%
Precio objetivo a 12 meses
1 analistas · 2026-08-14
Mín
$20.00
Máx
$20.00
Objetivo mediano
$20.00
+107,3%
Objetivo medio
$20.00
+107,3%
Historial de Ganancias EPS real vs estimado, sorpresa %, tasa de aciertos, próxima fecha de resultados
Sorpresa Media
-0.25%
| Período | EPS Actual | EPS est. | Sorpresa |
|---|---|---|---|
| 30 de junio de 2026 | $-0.58 | $-0.59 | 0.01% |
| 31 de marzo de 2026 | $-0.58 | $-0.67 | 0.09% |
| 31 de diciembre de 2025 | $0.81 | $-1.70 | 2.5% |
| 30 de septiembre de 2025 | $-0.08 | $-0.42 | 0.34% |
| 30 de junio de 2025 | $-2.24 | $-1.13 | -1.1% |
| 31 de marzo de 2025 | $-2.52 | $1.34 | -3.9% |
| 31 de diciembre de 2024 | $-2.80 | $-3.06 | 0.26% |
Comparación de pares (subindustria GICS) Métricas clave frente a competidores del sector
| Ticker | Capitalización Bursátil | P/E | Ingresos interanuales | Margen Neto | ROE | Margen Bruto |
|---|---|---|---|---|---|---|
| XLO | $3M | -0.2 | 589.9% | -80.0% | -165.5% | — |
| INMB | $41M | -0.8 | 257.1% | -91866.0% | -175.3% | — |
| EXOZ | $92M | -10.0 | — | — | -172.3% | — |
| INKT | — | -3.8 | 4.5% | -6931.8% | 63.4% | — |
| CLNN | $64M | — | -41.5% | -13086.5% | 200.2% | — |
| RNXT | — | -2.6 | 2511.6% | — | — | — |
| TCRX | — | -1.0 | 266.7% | -1256.8% | -86.6% | — |
| APLM | — | — | — | — | — | — |
| ATYR | $77M | -1.0 | -19.1% | -39009.5% | -107.8% | — |
Fundamentales Completos Todas las métricas por año — estado de resultados, balance general, flujo de caja
Estado de resultados 13
| Métrica | Tendencia | 2025 | 2024 |
|---|---|---|---|
| Revenue | $44M | $6M | |
| R&D Expense | $56M | $41M | |
| SG&A Expense | $30M | $25M | |
| Operating Expenses | $86M | $67M | |
| Operating Income | $-42M | $-61M | |
| Other Non-op | $1M | $2M | |
| Pretax Income | $-35M | $-58M | |
| Income Tax | $0 | $0 | |
| Net Income | $-35M | $-58M | |
| EPS (Basic) | $-4.19 | $-15.24 | |
| EPS (Diluted) | $-4.19 | $-15.24 | |
| Shares (Basic) | 8,359,109 | 3,822,244 | |
| EBITDA | $-40M | $-59M |
Balance general 18
| Métrica | Tendencia | 2025 | 2024 |
|---|---|---|---|
| Cash & Equivalents | $138M | $55M | |
| Prepaid Expense | $2M | $5M | |
| Current Assets | $145M | $60M | |
| PP&E (Net) | $4M | $4M | |
| PP&E (Gross) | $13M | $12M | |
| Accum. Depreciation | $9M | $7M | |
| Total Assets | $155M | $71M | |
| Accounts Payable | $3M | $3M | |
| Accrued Liabilities | $12M | $10M | |
| Current Liabilities | $56M | $27M | |
| Capital Leases | $6M | $7M | |
| Total Liabilities | $119M | $53M | |
| Common Stock | $0 | $5.0K | |
| Paid-in Capital | $454M | $401M | |
| Retained Earnings | $-419M | $-384M | |
| Stockholders' Equity | $35M | $18M | |
| Liabilities + Equity | $155M | $71M | |
| Shares Outstanding | 4,530,641 | 3,268,299 |
Flujo de Efectivo 10
| Métrica | Tendencia | 2025 | 2024 |
|---|---|---|---|
| D&A | $2M | $2M | |
| Stock-based Comp | $7M | $6M | |
| Restructuring | · | $937.0K | |
| Other Non-cash | $22M | $32M | |
| Operating Cash Flow | $-5M | $-18M | |
| CapEx | $518.0K | $36.0K | |
| Investing Cash Flow | $-518.0K | $-36.0K | |
| Financing Cash Flow | $88M | $29M | |
| Net Change in Cash | $82M | $11M | |
| Free Cash Flow | $-6M | $-18M |
Rentabilidad 7
| Métrica | Tendencia | 2025 | 2024 |
|---|---|---|---|
| Operating Margin | -95.9% | -955.0% | |
| Net Margin | -80.0% | -918.1% | |
| Pretax Margin | -80.0% | · | |
| EBITDA Margin | -92.4% | -929.0% | |
| ROA | -31.0% | -88.2% | |
| ROE | -165.5% | -302.0% | |
| ROIC | -119.0% | · |
Liquidez y Solvencia 2
| Métrica | Tendencia | 2025 | 2024 |
|---|---|---|---|
| Current Ratio | 2.6 | 2.2 | |
| Quick Ratio | 2.4 | 2.0 |
Eficiencia 1
| Métrica | Tendencia | 2025 | 2024 |
|---|---|---|---|
| Asset Turnover | 0.4 | 0.1 |
Tasas de Crecimiento 1
| Métrica | Tendencia | 2025 | 2024 |
|---|---|---|---|
| Revenue YoY | 589.9% | · |
Valoración (TTM) 10
| Métrica | Tendencia | 2025 | 2024 |
|---|---|---|---|
| Revenue TTM | $44M | $6M | |
| Net Income TTM | $-35M | $-58M | |
| Market Cap | $3M | $44M | |
| P/E | -0.2 | -0.1 | |
| P/S | 0.1 | 6.9 | |
| P/B | 0.1 | 2.5 | |
| P / Tangible Book | 0.1 | 2.5 | |
| P / Cash Flow | -0.6 | -2.4 | |
| P / FCF | -0.5 | -2.4 | |
| Earnings Yield | -654.7% | -1595.8% |
Estado de resultados 11
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $19M | $13M | $14M | $19M | $8M | $3M | $2M | $2M | $2M | |
| R&D Expense | $15M | $20M | $18M | $14M | $15M | $8M | $9M | $11M | $11M | |
| SG&A Expense | $8M | $7M | $7M | $7M | $7M | $9M | $7M | $6M | $6M | |
| Operating Expenses | $22M | $27M | $26M | $21M | $22M | $17M | $15M | $17M | $17M | |
| Operating Income | $-3M | $-14M | $-12M | $-2M | $-14M | $-14M | $-14M | $-15M | $-15M | |
| Other Non-op | $1M | $1M | $921.0K | $1M | $-1M | $586.0K | $536.0K | $742.0K | $779.0K | |
| Net Income | $-6M | $-10M | $10M | $-16M | $-16M | $-13M | $-13M | $-14M | $-14M | |
| EPS (Basic) | $-0.33 | $-0.58 | $-3.74 | $-0.11 | $-2.30 | $-2.49 | $-14.16 | $-0.22 | $-0.24 | |
| EPS (Diluted) | $-0.33 | $-0.58 | $-3.74 | $-0.11 | $-2.30 | $-2.49 | $-14.16 | $-0.22 | $-0.24 | |
| Shares (Basic) | 19,404,688 | 16,347,538 | -306,895,796 | 144,106,869 | 6,889,119 | 5,335,740 | -145,315,581 | 63,465,063 | 57,760,178 | |
| EBITDA | $-3M | · | · | $-2M | $-14M | $-13M | · | $-15M | $-15M |
Balance general 19
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $136M | $150M | $138M | $104M | $122M | $89M | $55M | $61M | $75M | |
| Prepaid Expense | $3M | $4M | $2M | $3M | $2M | $4M | $5M | $2M | $3M | |
| Current Assets | $145M | $154M | $145M | $124M | $124M | $93M | $60M | $63M | $78M | |
| PP&E (Net) | $3M | $4M | $4M | $4M | $4M | $4M | $4M | $5M | $5M | |
| PP&E (Gross) | $13M | $13M | $13M | $12M | $12M | $12M | $12M | $12M | $12M | |
| Accum. Depreciation | $9M | $9M | $9M | $8M | $8M | $8M | $7M | $7M | $7M | |
| Other Non-current Assets | · | · | · | · | · | · | · | · | $92.0K | |
| Total Assets | $154M | $163M | $155M | $134M | $134M | $104M | $71M | $75M | $90M | |
| Accounts Payable | $2M | $1M | $3M | $2M | $4M | $2M | $3M | $972.0K | $1M | |
| Accrued Liabilities | $8M | $9M | $12M | $9M | $6M | $4M | $10M | $10M | $10M | |
| Current Liabilities | $34M | $43M | $56M | $56M | $53M | $48M | $27M | $38M | $39M | |
| Capital Leases | $5M | $5M | $6M | $6M | $6M | $7M | $7M | $7M | $8M | |
| Total Liabilities | $82M | $91M | $119M | $142M | $127M | $93M | $53M | $54M | $56M | |
| Common Stock | $1.0K | $1.0K | · | $5.0K | $5.0K | $5.0K | · | $4.0K | $4.0K | |
| Paid-in Capital | $507M | $501M | $454M | $421M | $420M | $408M | $401M | $392M | $390M | |
| Retained Earnings | $-435M | $-428M | $-419M | $-429M | $-413M | $-397M | $-384M | $-371M | $-357M | |
| Stockholders' Equity | $72M | $73M | $35M | $-8M | $7M | $11M | $18M | $21M | $33M | |
| Liabilities + Equity | $154M | $163M | $155M | $134M | $134M | $104M | $71M | $75M | $90M | |
| Shares Outstanding | 6,580,149 | 5,782,536 | 4,530,641 | 51,829,013 | 51,827,910 | 51,775,264 | 3,268,299 | 43,958,074 | 43,951,922 |
Flujo de Efectivo 10
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $331.0K | $344.0K | $323.0K | $340.0K | $381.0K | $497.0K | $376.0K | $380.0K | $445.0K | |
| Stock-based Comp | $2M | $2M | $3M | $1M | $1M | $2M | $2M | $2M | $2M | |
| Restructuring | · | · | · | · | · | · | $0 | $-41.0K | $30.0K | |
| Other Non-cash | · | · | · | · | · | $40M | · | · | · | |
| Operating Cash Flow | $-19M | $-22M | $-2M | $-17M | $-14M | $29M | $-14M | $-14M | $20M | |
| CapEx | $19.0K | $556.0K | $95.0K | $0 | $401.0K | $22.0K | $6.0K | $9.0K | · | |
| Investing Cash Flow | $-19.0K | $-556.0K | $-95.0K | $0 | $-401.0K | $-22.0K | $-6.0K | $-9.0K | · | |
| Financing Cash Flow | $4M | $36M | $36M | $-285.0K | $47M | $5M | $8M | $-3.0K | $20M | |
| Net Change in Cash | $-14M | $13M | $34M | $-18M | $32M | $34M | $-6M | $-14M | $40M | |
| Free Cash Flow | · | · | · | · | · | $29M | · | · | · |
Rentabilidad 5
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -18.7% | · | · | -10.1% | -177.7% | -472.7% | · | -652.3% | -623.8% | |
| Net Margin | -34.1% | · | · | -85.4% | -196.0% | -452.7% | · | -619.5% | -590.8% | |
| EBITDA Margin | -18.7% | · | · | -10.1% | -177.7% | -455.8% | · | -652.3% | -623.8% | |
| ROA | -4.4% | · | · | -15.6% | -14.2% | -14.2% | · | -18.4% | -15.3% | |
| ROE | -16.1% | · | · | -252.9% | -78.3% | -72.8% | · | -38.2% | -27.6% |
Liquidez y Solvencia 2
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.3 | 3.6 | · | 2.2 | 2.3 | 2.0 | · | 1.7 | 2.0 | |
| Quick Ratio | 4.0 | · | · | 1.8 | 2.3 | 1.9 | · | 1.6 | 1.9 |
Eficiencia 1
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | · | · | 0.2 | 0.1 | 0.0 | · | 0.0 | 0.0 |
Valoración (TTM) 10
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $58M | $43M | · | $32M | $16M | · | · | · | · | |
| Net Income TTM | $-48M | $-55M | · | $-59M | $-57M | $-58M | · | $-62M | $-67M | |
| Market Cap | $63M | · | · | $44M | $35M | $37M | · | $35M | $42M | |
| P/E | -2.9 | -1.5 | · | -1.3 | -0.8 | -0.6 | · | -0.5 | -0.4 | |
| P/S | 1.1 | · | · | 1.4 | 2.3 | · | · | · | · | |
| P/B | 0.9 | · | · | -5.4 | 5.0 | 3.5 | · | 1.7 | 1.2 | |
| P / Tangible Book | 0.9 | 0.7 | · | · | 5.0 | 3.5 | · | 1.7 | 1.2 | |
| P / Cash Flow | · | · | · | · | · | 1.3 | · | · | · | |
| P / FCF | · | · | · | · | · | 1.3 | · | · | · | |
| Earnings Yield | -34.7% | -65.2% | · | -79.5% | -117.7% | -174.0% | · | -214.5% | -228.9% |
Estados Financieros Estado de resultados, balance general, flujo de caja — anual, últimos 5 años
Estado de resultados
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Ingresos | $44M | $6M | — | — | — |
| Margen Operativo % | -95.9% | -955.0% | — | — | — |
| Beneficio neto | $-35M | $-58M | $-76M | $-88M | $-76M |
| EPS Diluido | $-4.19 | $-15.24 | $-2.78 | $-3.22 | $-13.52 |
Balance general
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Deuda / Patrimonio | — | — | 0.1 | — | — |
| Ratio corriente | 2.6 | 2.2 | 3.0 | — | 15.8 |
| Ratio Rápido | 2.4 | 2.0 | 2.8 | — | 15.5 |
Flujo de Efectivo
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Flujo de caja libre | $-6M | $-18M | $-69M | — | $-82M |
Mis Métricas Tu lista de seguimiento personal — filas seleccionadas de Fundamentales Completos
📊
Elige las métricas que te importan — haz clic en el ➕ junto a cualquier fila en Fundamentales Completos arriba.
Tu selección se guarda y te sigue en todos los tickers.
Propietarios institucionales (13F) 3 declarantes · $8.2M total · A fecha de 30 de junio de 2026
Instituciones que informan tener esta acción en su Formulario 13F trimestral de la SEC. Solo posiciones largas; un solo presentador puede aparecer dos veces para tramos de opciones separados. Las patas de put/call de compensación grandes suelen reflejar la creación de mercado o el inventario cubierto, no la convicción direccional.
Actividad institucional — Q2 2026 vs trimestre anterior
| Nuevas posiciones | Posiciones cerradas | Aumentado | Disminuido | Cambio neto de acciones |
|---|---|---|---|---|
| 0 (0 vs trimestre anterior) | 0 (-35 vs trimestre anterior) | 0 (0 vs trimestre anterior) | 0 (-1 vs trimestre anterior) | 0 |
Comparado con Q1 2026. Las presentaciones del Formulario 13F de la SEC vencen dentro de los 45 días posteriores al final del trimestre, más un pequeño margen para los presentadores tardíos; los trimestres que aún se encuentran dentro de esa ventana se omiten en favor del par más reciente completamente reportado.
| Institución | Valor | Acciones | % de 13F rastreadas | Tipo |
|---|---|---|---|---|
| GILEAD SCIENCES, INC. | $6 230 727 | 650 389 | 76,24% | Acciones |
| TAKEDA PHARMACEUTICAL CO LTD | $1 243 084 | 1 475 121 | 15,21% | Acciones |
| VANGUARD GROUP INC | $698 605 | 1 091 570 | 8,55% | Acciones |
Informantes de la empresa 21 insiders · 6 directivos · 11 consejeros
| Insider | Rol | Última actividad | Acciones en propiedad | Compras 12m | Ventas 12m | Neto 12m |
|---|---|---|---|---|---|---|
| Rene Russo | PRESIDENT AND CEO | 1 de enero de 2026 M | 325 422 | 0 | 0 | $0 |
| Christopher James Frankenfield | Chief Financial Officer | 1 de enero de 2026 M | 24 766 | 0 | 1 | $-4 499 |
| Salvatore Giovine | Chief Financial Officer | 21 de octubre de 2021 A | — | 0 | 0 | $0 |
| Martin H. Huber Jr. | President of R&D and CMO | 21 de octubre de 2021 A | — | 0 | 0 | $0 |
| Katarina Luptakova | CHIEF MEDICAL OFFICER | 1 de enero de 2026 M | 33 250 | 0 | 0 | $0 |
| Kevin M. Brennan | SVP, FINANCE AND ACCOUNTING | 1 de enero de 2026 M | 6 371 | 0 | 1 | $-1 169 |
| Akintunde Olatokumbo Bello | Consejero | 11 de junio de 2026 A | — | 0 | 0 | $0 |
| Daniel J. Curran | Consejero | 11 de junio de 2026 A | — | 0 | 0 | $0 |
| Yuan Xu | Consejero | 11 de junio de 2026 A | — | 0 | 0 | $0 |
| Robert W. Ross | Consejero | 11 de junio de 2026 A | — | 0 | 0 | $0 |
| Aoife Brennan | Consejero | 11 de junio de 2026 A | — | 0 | 0 | $0 |
| Sara Bonstein | Consejero | 11 de junio de 2026 A | — | 0 | 0 | $0 |
| James Samuel Shannon | Consejero | 11 de junio de 2026 A | 10 000 | 1 | 0 | $43 950 |
| Cheryl R Blanchard | Consejero | 15 de abril de 2026 A | — | 0 | 0 | $0 |
| Paul J Clancy | Consejero | 26 de octubre de 2021 A | — | 0 | 0 | $0 |
| Michael Jay Ross | Consejero | 21 de octubre de 2021 A | — | 0 | 0 | $0 |
| Merck KGaA | Propietario del 10% | 26 de octubre de 2021 C | 680 825 | 0 | 0 | $0 |
| RiverVest Venture Fund IV, L.P. | Propietario del 10% | 26 de octubre de 2021 C | 1 441 444 | 0 | 0 | $0 |
| BAY CITY CAPITAL LLC | Propietario del 10% | 26 de octubre de 2021 C | 1 129 490 | 0 | 0 | $0 |
| FIL Ltd | — | 26 de octubre de 2021 C | 218 705 | 0 | 0 | $0 |
| FMR LLC | — | 26 de octubre de 2021 C | 4 465 | 0 | 0 | $0 |
Informantes de las presentaciones SEC Form 3/4/5; neto = solo P/S de mercado abierto
Activistas y propietarios del %+ 5 2 tenencias
Inversores que presentaron el Anexo 13D de la SEC — propiedad beneficiosa superior al % 5 con la intención de influir en el emisor (participaciones activistas, campañas de la junta directiva, M&A). Cada fila muestra el estado conocido más reciente de la posición de ese declarante.
| Declarante | Presentado | Participación | Estado | Propósito | Presentación |
|---|---|---|---|---|---|
| Persona informante no revelada, Persona informante no revelada, Persona informante no revelada | 5 de noviembre de 2021 | — | Presentación inicial | — | SEC |
| SV7 Impact Medicine Fund LP, SV7 (IMF) GP LLP | 3 de noviembre de 2021 | — | Presentación inicial | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Propiedad de ETFs Mantenido por 3 ETFs
El peso refleja solo las tenencias directas de acciones (N-PORT); los fondos apalancados o basados en derivados pueden tener exposición adicional a swaps no mostrada.